Compare GSK plc (GSK) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Tripadvisor Inc Common Stock — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while Tripadvisor Inc Common Stock trades at $14.7 (market cap $1.70B). The key difference: GSK plc is far larger — about 59.6× Tripadvisor Inc Common Stock's market cap, and GSK plc pays a 3.49% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| GSK | TRIP | |
|---|---|---|
Market Cap | $101.34B | $1.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $19.14 |
52-Week Low | $36.20 | $9.24 |
Enterprise Value | $121.95B | $1.82B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
TRIP trades at $14.36, up 2.57% today, with a bullish technical signal from moving averages and a neutral RSI near 67. Recent Q2 2026 earnings are pending, following mixed Q1 results. The company's $700 million sale of TheFork to American Express (Reuters, 2026-06-15) provides cash but highlights strategic refocusing. Revenue grew to $1.89 billion in 2025, though net margins are thin at 0.99%, and the P/E ratio of 132.73 suggests high earnings expectations relative to current profits.
Outlook is cautious; analyst consensus is a Hold (60.72%) with a $13.87 price target below current levels, indicating skepticism. Opportunities include leveraging the TheFork sale proceeds for core travel growth, but risks involve competitive pressures and inconsistent earnings. The stock's high valuation requires strong future performance to justify, with macroeconomic factors like inflation posing additional headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
